Compare Stocks: BDTX, EDIT, CCCC, and ARCT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$14.74 -5.7%	$9.29	$5.50 ▼ $24.17	$444.25M	2.48	1.49 million shs	722,953 shs
BDTX Black Diamond Therapeutics	$2.10	$1.97	$1.60 ▼ $4.94	$120.65M	3.31	516,056 shs	402,388 shs
CCCC C4 Therapeutics	$3.44 -3.1%	$3.88	$1.69 ▼ $5.17	$436.74M	2.94	2.24 million shs	1.44 million shs
EDIT Editas Medicine	$2.77 -8.6%	$3.02	$1.66 ▼ $4.54	$465.35M	2.09	2.50 million shs	2.96 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	-1.20%	-3.70%	+110.93%	+126.85%	-12.39%
BDTX Black Diamond Therapeutics	-0.94%	+2.94%	+7.69%	+13.51%	-31.15%
CCCC C4 Therapeutics	-5.59%	-8.27%	-4.83%	-8.27%	+31.00%
EDIT Editas Medicine	-6.19%	-1.30%	+5.21%	+22.18%	+8.60%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$14.74 -5.7%	$9.29	$5.50 ▼ $24.17	$444.25M	2.48	1.49 million shs	722,953 shs
BDTX Black Diamond Therapeutics	$2.10	$1.97	$1.60 ▼ $4.94	$120.65M	3.31	516,056 shs	402,388 shs
CCCC C4 Therapeutics	$3.44 -3.1%	$3.88	$1.69 ▼ $5.17	$436.74M	2.94	2.24 million shs	1.44 million shs
EDIT Editas Medicine	$2.77 -8.6%	$3.02	$1.66 ▼ $4.54	$465.35M	2.09	2.50 million shs	2.96 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	-1.20%	-3.70%	+110.93%	+126.85%	-12.39%
BDTX Black Diamond Therapeutics	-0.94%	+2.94%	+7.69%	+13.51%	-31.15%
CCCC C4 Therapeutics	-5.59%	-8.27%	-4.83%	-8.27%	+31.00%
EDIT Editas Medicine	-6.19%	-1.30%	+5.21%	+22.18%	+8.60%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	2.60	Moderate Buy	$23.00	56.04% Upside
BDTX Black Diamond Therapeutics	2.64	Moderate Buy	$10.25	388.10% Upside
CCCC C4 Therapeutics	2.60	Moderate Buy	$7.67	122.87% Upside
EDIT Editas Medicine	2.60	Moderate Buy	$6.00	116.61% Upside

Current Analyst Ratings Breakdown

Latest BDTX, EDIT, CCCC, and ARCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	ARCT Arcturus Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$41.00
8/18/2026	EDIT Editas Medicine	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$6.00
8/11/2026	EDIT Editas Medicine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/6/2026	BDTX Black Diamond Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/6/2026	BDTX Black Diamond Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/6/2026	BDTX Black Diamond Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/17/2026	ARCT Arcturus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	CCCC C4 Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	EDIT Editas Medicine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	BDTX Black Diamond Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)

(Data available from 9/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$18.72M	22.38	N/A	N/A	$7.53 per share	1.96
BDTX Black Diamond Therapeutics	N/A	N/A	$0.52 per share	4.02	$1.97 per share	N/A
CCCC C4 Therapeutics	$35.04M	12.08	N/A	N/A	$2.65 per share	1.30
EDIT Editas Medicine	$40.52M	10.50	N/A	N/A	$0.28 per share	9.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$65.78M	-$3.31	N/A	N/A	N/A	-317.62%	-46.54%	-36.46%	11/9/2026 (Estimated)
BDTX Black Diamond Therapeutics	$22.37M	-$0.75	N/A	N/A	N/A	N/A	-32.10%	-25.21%	11/5/2026 (Estimated)
CCCC C4 Therapeutics	-$104.99M	-$1.00	N/A	N/A	N/A	-289.44%	-45.45%	-30.90%	11/5/2026 (Estimated)
EDIT Editas Medicine	-$160.06M	-$0.75	N/A	N/A	N/A	-157.32%	-196.63%	-38.17%	11/9/2026 (Estimated)

Latest BDTX, EDIT, CCCC, and ARCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	CCCC C4 Therapeutics	-$0.2264	-$0.18	+$0.0464	-$0.18	$4.00 million	$6.64 million
8/7/2026	Q2 2026	ARCT Arcturus Therapeutics	-$0.9964	-$0.84	+$0.1564	-$0.84	$3.11 million	$2.96 million
8/5/2026	Q2 2026	BDTX Black Diamond Therapeutics	-$0.1954	-$0.17	+$0.0254	-$0.17	$5.56 million	N/A
8/5/2026	Q2 2026	EDIT Editas Medicine	-$0.2705	-$0.15	+$0.1205	-$0.15	$2.85 million	$11.89 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	$0.71	4.85%	N/A	N/A	N/A
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	N/A
CCCC C4 Therapeutics	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	N/A	5.88	5.88
BDTX Black Diamond Therapeutics	N/A	7.28	7.28
CCCC C4 Therapeutics	N/A	5.45	5.45
EDIT Editas Medicine	N/A	3.19	3.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
BDTX Black Diamond Therapeutics	95.47%
CCCC C4 Therapeutics	78.81%
EDIT Editas Medicine	71.90%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	17.80%
BDTX Black Diamond Therapeutics	9.29%
CCCC C4 Therapeutics	5.60%
EDIT Editas Medicine	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	28.42 million	23.36 million	Optionable
BDTX Black Diamond Therapeutics	90	57.45 million	52.12 million	Optionable
CCCC C4 Therapeutics	150	123.03 million	116.14 million	Optionable
EDIT Editas Medicine	230	153.58 million	148.82 million	Optionable

BDTX, EDIT, CCCC, and ARCT Headlines

Recent News About These Companies

Editas Medicine Reports Inducement Grants to New Chief Medical Officer

September 9 at 1:06 PM | finance.yahoo.com

Editas Medicine Reports Inducement Grants to New Chief Medical Officer

September 9 at 9:00 AM | globenewswire.com

Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401

September 9 at 7:01 AM | marketbeat.com

Editas Medicine Names Dan Ory Chief Medical Officer

September 8 at 9:58 AM | rttnews.com

Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer

September 8 at 9:58 AM | finance.yahoo.com

Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer

September 8 at 7:00 AM | globenewswire.com

Editas Medicine (NASDAQ:EDIT) CEO Gilmore Neil O'neill Sells 5,124 Shares

September 5, 2026 | insidertrades.com

Seven Fleet Capital Management LP Takes Position in Editas Medicine, Inc. $EDIT

September 5, 2026 | marketbeat.com

Editas Medicine (NASDAQ:EDIT) CEO Gilmore Neil O'neill Sells 5,124 Shares of Stock

September 4, 2026 | marketbeat.com

Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?

September 4, 2026 | finance.yahoo.com

Editas: Slow Progress Doesn't Mean No Progress For In-Vivo Gene Editor

September 2, 2026 | seekingalpha.com

Editas Medicine Files $400 Million Mixed Shelf

September 2, 2026 | marketscreener.comM

BlackRock Inc. Takes Position in Editas Medicine, Inc. $EDIT

September 2, 2026 | marketbeat.com

Editas Medicine to Participate in Upcoming Investor Conferences

September 1, 2026 | finance.yahoo.com

Editas Medicine to Participate in Upcoming Investor Conferences

September 1, 2026 | globenewswire.com

Zacks Research Predicts Higher Earnings for Editas Medicine

August 30, 2026 | americanbankingnews.com

Nantahala Capital Management LLC Acquires Shares of 852,700 Editas Medicine, Inc. $EDIT

August 29, 2026 | marketbeat.com

Zacks Research Lifts Earnings Estimates for Editas Medicine

August 28, 2026 | marketbeat.com

Seven Fleet Capital Management LP Purchases Shares of 1,330,500 Editas Medicine, Inc. $EDIT

August 27, 2026 | marketbeat.com

ADAR1 Capital Management LLC Buys New Stake in Editas Medicine, Inc. $EDIT

August 26, 2026 | marketbeat.com

Editas Medicine (NASDAQ:EDIT) Stock Price Up 10.5% - Time to Buy?

August 25, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BDTX, EDIT, CCCC, and ARCT Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$14.74 -0.89 (-5.69%)

Closing price 04:00 PM Eastern

Extended Trading

$14.68 -0.05 (-0.37%)

As of 07:44 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Black Diamond Therapeutics NASDAQ:BDTX

$2.10 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$2.10 0.00 (0.00%)

As of 07:36 PM Eastern

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

C4 Therapeutics NASDAQ:CCCC

$3.44 -0.11 (-3.10%)

Closing price 04:00 PM Eastern

Extended Trading

$3.47 +0.03 (+0.84%)

As of 07:57 PM Eastern

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Editas Medicine NASDAQ:EDIT

$2.77 -0.26 (-8.58%)

Closing price 04:00 PM Eastern

Extended Trading

$2.80 +0.04 (+1.26%)

As of 07:30 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BDTX, EDIT, CCCC, and ARCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BDTX, EDIT, CCCC, and ARCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BDTX, EDIT, CCCC, and ARCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BDTX, EDIT, CCCC, and ARCT Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

Black Diamond Therapeutics NASDAQ:BDTX

C4 Therapeutics NASDAQ:CCCC

Editas Medicine NASDAQ:EDIT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BDTX, EDIT, CCCC, and ARCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BDTX, EDIT, CCCC, and ARCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BDTX, EDIT, CCCC, and ARCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BDTX, EDIT, CCCC, and ARCT Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

Black Diamond Therapeutics NASDAQ:BDTX

C4 Therapeutics NASDAQ:CCCC

Editas Medicine NASDAQ:EDIT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools